Abstract
The extracellular domain of the receptor tyrosine kinase Tie2/TEK (exTEK) has been used as an angiopoietin decoy to study the role of angiopoietins in the tumor–host interactions, using a syngeneic model of experimental metastases and subcutaneous tumor. Soluble exTEK secreted by transfected tumor cells inhibited HUVECs from forming tubes in Matrigel. ExTEK-transfected C26 colon carcinoma and TS/A mammary tumor cells displayed reduced growth rate when injected subcutaneously, and reduced ability to form experimental metastases when injected intravenously. Immunohistochemical analysis of tumors and metastases showed increased leukocytes infiltration and signs of inflammation in exTEK-secreting compared to parental tumor, as well as impairment in neo-vessel growth and organization. However, while neoangiogenesis eventually rescued in the subcutis, it failed to organize in the experimental metastases of exTEK-secreting tumor, contributing to the hampering of metastatic growth and to increased mice survival. The reactive infiltrate of C26TEK contained a different percentage of leukocytes and was responsible for the tumor inhibition. In fact, leukopenia induced by γ-irradiation of recipient mice or injection into interferon gamma (IFN-γ) gene knockout (GKO) mice resulted in reduced mouse survival and an increased number of lung metastases. On the other hand, interleukin (IL)-12 treatment prolonged the survival of mice bearing subcutaneous C26TEK but not of those bearing lung metastases, suggesting that IL-12 could exert further antiangiogenic effects at the site where the tumor can restore neoangiogenesis. These results show in vivo that reduced angiopoietin availability at the tumor site induces a local inflammatory response and impairment of neoangiogenesis which act synergistically to limit tumor growth and metastasis.








Similar content being viewed by others
Abbreviations
- AEC:
-
amino-ethylcarbazole
- ELISA:
-
enzyme-linked immunosorbent assay
- HRP:
-
horseradish peroxidase
- HUVEC:
-
human umbilical vascular endothelial cell
- i.v.:
-
intravenous
- s.c.:
-
subcutaneous
- TBS:
-
Tris-HCl buffered solution
References
Boggio K, Di Carlo E, Rovero S, Cavallo F, Quaglino E, Lollini PL, Nanni P, Nicoletti G, Wolf S, Musiani P, Forni G (2000) Ability of systemic IL-12 to hamper progressive stages of mammary carcinogenesis in HER2/neu transgenic mice. Cancer Res 60:359
Buckeley CD, Pilling D, Lord JM, Akbar AN, Scheel-Toellner D, Salmon M (2001) Fibroblasts regulate the switch from acute resolving to chronic persistent inflammation. Trends Immunol 22:199
Butcher EC, Williams M, Youngman K, Rott L, Briskin M (1999) Lymphocyte trafficking and regional immunity. Adv Immunol 72:209
Colombo MP, Ferrari G, Stoppacciaro A, Parenza M, Rodolfo M, Mavilio F, Parmiani G (1991) Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo. J Exp Med 173:889
Colombo MP, Lombardi L, Stoppacciaro A, Melani C, Parenza M, Bottazzi B, Parmiani G (1992) Granulocyte colony-stimulating factor (G-CSF) gene transduction in murine adenocarcinoma drives neutrophil-mediated tumor inhibition in vivo. J Immunol 149:113
Coughlin CM, Salhany KE, Gee MS, LaTemple DC, Kotenko S, Ma X, Gri G, Wysocha M, Kim JE, Liu L, Liao F, Farber JM, Pestka S, Trinchieri G, Lee WM (1998) Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity 9:25
Coussens LM, Werb Z (2001) Inflammatory cells and cancer: think different! J Exp Med 193:F23
Dalton DK, Pitts-Meek S, Keshav S, Figari IS, Bradley A, Stewart TA (1993) Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. Science 259:1739
Dumont DJ, Gradwohl GJ, Fong GH, Auerbach R, Breitman ML (1993) The endothelial-specific receptor tyrosine kinase, tek, is a member of a new subfamily of receptors. Oncogene 8:1293
Foda HD, Zucker S (2001) Matrix metalloproteinases in cancer invasion, metastasis and angiogenesis. Drug Discov Today 6:478
Gamble JR, Drew J, Trezise L, Underwood A, Parsons M, Kasminkas L, Rudge J, Yancopoulos G, Vadas MA (2000) Angiopoietin-1 is an antipermeability and anti-inflammatory agent in vitro and targets cell junctions. Circ Res 87:603
Goede V, Schmidt T, Kimina S, Kozian D, Augustin HG (1998) Analysis of blood vessel maturation process during cyclic ovarian angiogenesis. Lab Invest 78:1385
Hanahan D (1997) Signaling vascular morphogenesis and maitenance. Science 277:48
Hayes AJ, Huang W, Mallah J, Yang D, Lippman ME, Li LY (1999) Angiopoietin-1 and its receptor Tie-2 participate in the regulation of capillary-like tubule formation and survival of endothelial cells. Microvasc. Res 58:224
Holash J, Wiegard SJ, Yancopoulos GD (1999) New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene 18:5356
Holash J, Maisonpierre P, Compton D, Boland P, Alexander CR, Zagzag D, Yancopoulos GD, Wiegand SJ (1999) Vessel cooption, regression and growth in tumors mediated by angiopoietins and VEGF. Science 284:1994
Kim I, Moon S, Park SK, Chae SW, Koh GY (2001) Angiopoietin-1 reduces VEGF-stimulated leukocyte adhesion to endothelial cells by reducing ICAM-1, VCAM-1, and E-selectin expression. Circ Res 89:477
Lin P, Polverini P, Dewhirst M, Shan S, Rao PS, Peters K (1997) Inhibition of tumor angiogenesis using a soluble receptor establishes a role for tie2 in pathologic vascular growth. J Clin Invest 100:2072
Lin P, Buxton JA, Acheson A, Radziejewski C, Maisonpierre PC, Yancopoulos GD, Channon KM, Hale LP, Dewhirst MW, George SE, Peters KG (1998) Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase tie2. Proc Natl Acad Sci U S A 95:8829
Maisonpierre PC, Suri C, Jones P, Bartunkova S, Wiegand SJ, Radziejewski C, Compton D, McClain J, Aldrich TH, Papadopoulos N, Daly TJ, Davis S, Sato TN, Yancopoulos GD (1997) Angiopoietin-2, a natural antagonist for tie2 that disrupts in vivo angiogenesis. Science 277:55
Mantovani A, Bottazzi B, Colotta F, Sozzani S, Ruco L (1992) The origin and function of tumor-asociated macrophages. Immunol Today 13:265
Melani C, Figini M, Nicosia D, Luison E, Ramakrishna V, Casorati G, Parmiani G, Eshhar Z, Canevari S, Colombo MP (1998) Targeting of interleukin-2 to human ovarian carcinoma by fusion with a single-chain Fv of antifolate receptor antibody. Cancer Res 58:4146
Nanni P, Di Giovanni C, Lollini PL, Nicoletti G, Prodi G (1983) TS/A: a new metastasizing cell line from a BALB/c spontaneous mammary carcinoma. Clin Exp Metastasis 1:373
Papapetropoulos A, Garcia-Cardena G, Dengler TJ, Maisonpierre PC, Yancopoulos GD, Sessa WC (1999) Direct action of angiopoietin-1 on human endothelium: evidence for network stabilization, cell survival, and interaction with other angiogenic growth factors. Lab Invest 79:213
Siemeister G, Sshirner M, Weindel K, Reusch P, Menrad A, Marme D, Martigny-Baron G (1999) Two independent mechanisms essential for tumor angiogenesis: inhibition of human melanoma xenograft growth by interfering with either the vascular endothelial growth factor receptor pathway or the tie-2 pathway. Cancer Res 59:3185
Stoppacciaro A, Melani C, Parenza M, Mastracchio A, Bassi C, Baroni C, Parmiani G, Colombo MP (1993) Regression of an established tumor genetically modified to release granulocyte colony-stimulating factor requires granulocyte-T cell cooperation and T cell-produced interferon gamma. J Exp Med 178:151
Stratmann A, Risau W, Plate KH (1998) Cell-type specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. Am J Pathol 153:1459
Stratmann A, Acker T, Burger AM, Amann K, Risau W, Plate KH (2001) Differential inhibition of tumor angiogenesis by tie2 and vascular endothelial growth factor receptor-2 dominant-negative receptor mutants. Int J Cancer 91:273
Thurston G, Suri C, Smith K, McClain J, Sato TN, Yancopoulos GD, McDonald DM (1999) Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 286:2511
Witzenbichler B, Maisonpierre PC, Jones P, Yancopoulos GD, Isner JM (1998) Chemotactic properties of angiopoietin-1 and −2, ligands for the endothelial-specific receptor tyrosine kinase Tie2. J Biol Chem 273:18514
Yano M, Iwama A, Nishio H, Suda J, Takada G, Suda T (1997) Expression and function of murine receptor tyrosine kinases, tie and tek, in hematopoietic stem cells. Blood 89:4317
Acknowledgements
This work was supported by the Italian Association for Cancer Research (AIRC), by the CNR (grant 99.02526.CT04), the Italian Ministry of University and Scientific Research (MURST), and the ISS Italy-USA Program on Tumor Therapy. We thank Mr Ivano Arioli and Ms Daniela Nicosia for their skillful technical assistance, and Mr Mario Azzini for art work. We are indebted to Dr Pengnian Charles Lin (Duke University Medical Center, Durham, NC) and Prof. Toshio Suda (Institute of Molecular Embryology and Genetics, Kumamoto University School of Medicine, Kumamoto, Japan) for providing the anti-Tie2/TEK-specific antibodies.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Melani, C., Stoppacciaro, A., Foroni, C. et al. Angiopoietin decoy secreted at tumor site impairs tumor growth and metastases by inducing local inflammation and altering neoangiogenesis. Cancer Immunol Immunother 53, 600–608 (2004). https://doi.org/10.1007/s00262-004-0500-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00262-004-0500-5